Switch to:
More From Other Websites
Regeneron: The More the Merrier? Jun 27 2017
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU Jun 27 2017
Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion Jun 27 2017
Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to... Jun 27 2017
Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with... Jun 27 2017
Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with... Jun 27 2017
[$$] Third Point Move Could Lead to Nestlé-L’Oréal Decoupling Jun 26 2017
Domino Effect: Nestle Sale of L'Oreal Could Trigger Sanofi Move Jun 26 2017
Good Companies From Warren Buffett's Portfolio Jun 23 2017
Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout Jun 23 2017
Vertex on the Street: Analysts’ Recommendations in June 2017 Jun 23 2017
Drugmakers May Lose $390B In Sales Over 5 Years Jun 22 2017
Shire (SHPG) Receives MAA Validation for Veyvondi by EMA Jun 22 2017
Eosinophilic Esophagitis: Major Market Opportunity for Dupixent? Jun 20 2017
Dupixent May Prove Effective in Multiple Diseases Jun 20 2017
Horizon Pharma Gets Health Canada Approval for Procysbi Jun 20 2017
Dupixent May Be a Major Growth Driver for Regeneron in 2017 Jun 20 2017
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio Jun 20 2017
Regeneron’s Praluent May See Gradual Increase in 2017 Demand Jun 20 2017
Sanofi: Should Value Investors Consider SNY Stock? Jun 19 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK